Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Biologics: Targets and Therapy · 2018-12 · Volume 13 · 1-12
DOI: 10.2147/btt.s114530 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biologics: Targets and Therapy, 2018-12. Verfasst von Michelle E Keyel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Patrick.Reynolds@ttuhsc.edu. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, Patrick.Reynolds@ttuhsc.edu.
- Department of Pediatrics, Patrick.Reynolds@ttuhsc.edu.
- Department of Internal Medicine, Patrick.Reynolds@ttuhsc.edu.
- Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA, Patrick.Reynolds@ttuhsc.edu.
Zitieren
APA
Keyel, M. E., & Reynolds, C. P. (2018). Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy, Volume 13, 1-12. https://doi.org/10.2147/btt.s114530
Vancouver
Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy. 2018;Volume 13:1-12. doi:10.2147/btt.s114530
BibTeX
@article{Keyel2018,
author = {Keyel, Michelle E and Reynolds, C Patrick},
title = {Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy},
journal = {Biologics: Targets and Therapy},
year = {2018},
volume = {Volume 13},
pages = {1--12},
doi = {10.2147/btt.s114530}
}
EUVIMED